Sanofi. (Photo: Dr. Avishai Reicher via Wikimedia Commons)
A federal appeals court on Thursday ordered a new trial in a high-profile patent infringement dispute over Sanofi’s drug Praluent and lifted a permanent injunctionbarring sales of the biologic, used to fight high cholesterol.
*May exclude premium content
Already have an account? Sign In Now
Interested in customizing your subscription with Law.com All Access?
Contact our Sales Professionals at 1-855-808-4530 or send an email to firstname.lastname@example.org to learn more.